Indoco Remedies Limited INDOCO.NS Stock
Indoco Remedies Limited Price Chart
Indoco Remedies Limited INDOCO.NS Financial and Trading Overview
Indoco Remedies Limited stock price | 347 INR |
Previous Close | 329.3 INR |
Open | 332.1 INR |
Bid | 330.55 INR x 0 |
Ask | 330.95 INR x 0 |
Day's Range | 329.9 - 333.5 INR |
52 Week Range | 306.4 - 423.9 INR |
Volume | 93.71K INR |
Avg. Volume | 131.84K INR |
Market Cap | 31.35B INR |
Beta (5Y Monthly) | 0.357876 |
PE Ratio (TTM) | 21.476315 |
EPS (TTM) | 10.99 INR |
Forward Dividend & Yield | 1.5 (0.47%) |
Ex-Dividend Date | September 14, 2022 |
1y Target Est | 403 INR |
INDOCO.NS Valuation Measures
Enterprise Value | 32.87B INR |
Trailing P/E | 21.476315 |
Forward P/E | 13.117321 |
PEG Ratio (5 yr expected) | 0.95 |
Price/Sales (ttm) | 1.8785316 |
Price/Book (mrq) | 2.966831 |
Enterprise Value/Revenue | 1.97 |
Enterprise Value/EBITDA | 11.489 |
Trading Information
Indoco Remedies Limited Stock Price History
Beta (5Y Monthly) | 0.357876 |
52-Week Change | -6.28% |
S&P500 52-Week Change | 20.43% |
52 Week High | 423.9 INR |
52 Week Low | 306.4 INR |
50-Day Moving Average | 332.4 INR |
200-Day Moving Average | 353.65 INR |
INDOCO.NS Share Statistics
Avg. Volume (3 month) | 131.84K INR |
Avg. Daily Volume (10-Days) | 183.26K INR |
Shares Outstanding | 92.15M |
Float | 36.31M |
Short Ratio | N/A |
% Held by Insiders | 60.07% |
% Held by Institutions | 18.45% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 2.25 |
Trailing Annual Dividend Yield | 0.68% |
5 Year Average Dividend Yield | 33.00% |
Payout Ratio | 0.09729999 |
Last Split Factor | 5:1 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | March 31, 2023 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | March 31, 2024 |
Profitability
Profit Margin | 8.52% |
Operating Margin (ttm) | 12.91% |
Gross Margin | 68.75% |
EBITDA Margin | 17.14% |
Management Effectiveness
Return on Assets (ttm) | 8.56% |
Return on Equity (ttm) | 14.71% |
Income Statement
Revenue (ttm) | 16.69B INR |
Revenue Per Share (ttm) | 181.11 INR |
Quarterly Revenue Growth (yoy) | 4.70% |
Gross Profit (ttm) | 11.47B INR |
EBITDA | 2.86B INR |
Net Income Avi to Common (ttm) | 1.42B INR |
Diluted EPS (ttm) | 15.41 |
Quarterly Earnings Growth (yoy) | -36.19% |
Balance Sheet
Total Cash (mrq) | 143.4M INR |
Total Cash Per Share (mrq) | 1.56 INR |
Total Debt (mrq) | 3.33B INR |
Total Debt/Equity (mrq) | 32.37 INR |
Current Ratio (mrq) | 1.904 |
Book Value Per Share (mrq) | 111.55 |
Cash Flow Statement
Operating Cash Flow (ttm) | 1.79B INR |
Levered Free Cash Flow (ttm) | -794630976 INR |
Profile of Indoco Remedies Limited
Country | India |
State | N/A |
City | Mumbai |
Address | Indoco House |
ZIP | 400098 |
Phone | 91 22 6287 1000 |
Website | https://www.indoco.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | 6000 |
Indoco Remedies Limited manufactures, markets, and sells formulations and active pharmaceutical ingredients in India and internationally. The company's products portfolio includes respiratory products, such as Karvol Plus, Febrex Plus, Dropizin, and Tuspel; stomatologicals products that include Sensodent-K, Sensoform Toothpaste, Sensoform Gum Paint, Rexidin M, Rexidin SRS, RR Sensoform Dental, Sensodent-KF, Poviclean, Rexidin, Sensodent-R, Snowdent, Kidodent, Rexidin Plus, and Dentogel; gastrointestinal products, such as Carmicide, Cyclopam, Cyclopam Plus, Cyclomeff, and Nosic; pain/analgesics products that include Lignox A and Lignox ; and ophthal/otologicals products, such as Renolen, Homide, Dexoren S, Zincoren, Bfloren, Dexoren, Otorex, Mofloren-D, Mofloren BF, Macuchek, and Mofloren LP. It also provides vitamins/minerals/nutrients that include Methycal, Cital UTI, SM Fibro, Coloferrin, Cal Aid, and MCBM DHA; urology products, such as Cital-H and Cital; Cloben G, Noxa, and Scabex for dermatology; ATM, Clygan, Vepan, and Oxipod for anti-infectives; Hemsyl for blood related therapies; MCBM 69 and D-Chiro for gynecological; Aloja and Aloja M for Anti-Diabetics; and Spear for anti-haemorrhoidal. In addition, the company provides analytical services, such as impurity profile, particle size analysis, heavy metal analysis, polymorphism and compatibility studies, extractables and leachables studies, lyophilization studies, reference and working standards, forced degradation studies, and chromatographic method development and validation services. Further, it offers architectural design, lighting, mechanical and utility engineering, project and construction management, electrical, control system, piping, structural design, data transfer system, and process engineering. The company was formerly known as Indo Continental Trading Company. Indoco Remedies Limited was founded in 1945 and is based in Mumbai, India.
Q&A For Indoco Remedies Limited Stock
What is a current INDOCO.NS stock price?
Indoco Remedies Limited INDOCO.NS stock price today per share is 347 INR.
How to purchase Indoco Remedies Limited stock?
You can buy INDOCO.NS shares on the NSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Indoco Remedies Limited?
The stock symbol or ticker of Indoco Remedies Limited is INDOCO.NS.
Which industry does the Indoco Remedies Limited company belong to?
The Indoco Remedies Limited industry is Drug Manufacturers-Specialty & Generic.
How many shares does Indoco Remedies Limited have in circulation?
The max supply of Indoco Remedies Limited shares is 92.18M.
What is Indoco Remedies Limited Price to Earnings Ratio (PE Ratio)?
Indoco Remedies Limited PE Ratio is 31.57416000 now.
What was Indoco Remedies Limited earnings per share over the trailing 12 months (TTM)?
Indoco Remedies Limited EPS is 10.99 INR over the trailing 12 months.
Which sector does the Indoco Remedies Limited company belong to?
The Indoco Remedies Limited sector is Healthcare.